Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
4.290
+0.190 (4.63%)
Dec 20, 2024, 4:00 PM EST - Market closed
Xenetic Biosciences Revenue
Xenetic Biosciences had revenue of $614.24K in the quarter ending September 30, 2024, with 0.50% growth. This brings the company's revenue in the last twelve months to $2.52M, up 7.15% year-over-year. In the year 2023, Xenetic Biosciences had annual revenue of $2.54M with 48.80% growth.
Revenue (ttm)
$2.52M
Revenue Growth
+7.15%
P/S Ratio
2.62
Revenue / Employee
$630,857
Employees
4
Market Cap
6.62M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
Dec 31, 2019 | 17.07K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Star Equity Holdings | 50.38M |
Syra Health | 7.74M |
Plus Therapeutics | 5.73M |
PAVmed | 4.03M |
Kindly MD | 2.88M |
ABVC BioPharma | 509.79K |
XBIO News
- 4 days ago - Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Accesswire
- 5 days ago - Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - Accesswire
- 16 days ago - Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - Accesswire
- 4 weeks ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Accesswire
- 6 weeks ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - Accesswire